NasdaqGS:RPRX
NasdaqGS:RPRXPharmaceuticals

Does Royalty Pharma’s 41% Rally in 2025 Signal a Stronger Outlook?

If you are weighing whether to jump into Royalty Pharma or considering if it is time to take some profits, you are not alone. This stock has become a topic of lively debate, especially as its recent run has caught the attention of both cautious and opportunistic investors. Over the past year, Royalty Pharma has delivered a total return of over 34%. What really stands out is its nearly 41% surge year-to-date. While its five-year numbers are barely in the red, the short-term momentum is...
NYSE:BSX
NYSE:BSXMedical Equipment

Is There Still Room for Growth in Boston Scientific After Strong 32% Rally?

Thinking about what to do with Boston Scientific stock? You are not alone. With the company’s shares up an impressive 17.7% year-to-date and a remarkable 32.2% over the past year, it is no wonder many investors are wondering if there is still room to grow, or if it is time to take some profits off the table. The stock’s five-year run, delivering an eye-catching 157.9% total return, speaks to strong momentum. However, this also raises questions about whether that growth is justified or coming...
NasdaqGS:ZM
NasdaqGS:ZMSoftware

What Recent AI Announcements Mean for Zoom’s Valuation in 2025

Deciding what to do with your Zoom Communications stock these days feels a little like trying to tune in to the right frequency, with so many signals flying around. After the wild swings of recent years, you might be wondering if now is the right time to buy, hold, or even walk away. The stock price, lately hovering around $73, has been on a bit of a roller coaster, down just over 10% year-to-date, but up about 7.5% in the past year. That back-and-forth movement says a lot about shifting...
NasdaqGS:CGON
NasdaqGS:CGONBiotechs

How Higher Losses and Escalating Expenses at CG Oncology (CGON) Have Changed Its Investment Story

CG Oncology, Inc. announced earnings results for the second quarter and first half of 2025, reporting a net loss of US$41.43 million for the quarter and US$75.88 million for the six months ended June 30, both sharply higher than a year earlier. The company's basic loss per share from continuing operations also increased substantially, highlighting escalating expenses or investment as a key theme in its financial performance. We'll explore how the increased net loss and rising loss per share...
NYSE:SQM
NYSE:SQMChemicals

Does SQM’s Sharp Drop in Quarterly Profits Signal a Shifting Growth Strategy?

On August 19, 2025, Sociedad Química y Minera de Chile S.A. reported that its second quarter sales and net income had declined meaningfully compared to the previous year, with net income dropping to US$88.4 million from US$213.6 million and revenue falling to US$1,042.7 million from US$1,293.6 million. An interesting aspect is that, despite the year-over-year declines in profitability for the quarter, the company turned a net profit for the first half of 2025 compared to a large net loss in...
NYSE:ABT
NYSE:ABTMedical Equipment

Abbott Laboratories (ABT): Assessing Current Valuation After Recent Share Price Momentum

If you are watching Abbott Laboratories (ABT) this week, the stock’s recent run-up might have you wondering if there is a new story unfolding. There is no single headline or corporate event moving shares, but the persistent climb in its price is starting to draw more investor attention. When a stock like Abbott moves higher without a big, clear-cut catalyst, it often prompts investors to dig deeper into what is really driving sentiment, especially with economic uncertainty still present in...
NasdaqCM:PLUG
NasdaqCM:PLUGElectrical

Should Investors Revisit Plug Power After 97% Jump and Green Hydrogen Funding Boost?

Thinking about what to do with Plug Power stock? You are not alone. With eye-popping short-term moves and nerve-wracking long-term slides, Plug Power’s stock has kept traders and investors on their toes. Just this past quarter, shares nearly doubled, climbing 97%, which stands out against the rougher ride over the last few years. With the price currently at $1.54 and still discounted about 28% compared to analyst targets, it is clear that expectations are shifting rapidly in both...
NYSE:CAG
NYSE:CAGFood

Does Conagra’s Recent Slump Signal a Discounted Opportunity for 2025?

If you have ever found yourself staring at Conagra Brands’ stock chart and debating your next move, you are not alone. The consumer staples giant, trading under the ticker symbol CAG, has certainly given investors a lot to think about lately. After a choppy year, the stock recently closed at $19.30, down just under 1% over the last month and more than 30% year-to-date. Longer-term performance tells a similar story, with the one-year total return sitting at -33% and five-year total return near...
NYSE:KD
NYSE:KDIT

Does Kyndryl’s Strong Cash Flow Outlook Signal Opportunity After Shares Fall 22% in June 2025?

If you have been eyeing Kyndryl Holdings and wondering whether now is the right moment to buy, hold, or even reconsider your strategy, you are not alone. The company's stock has seen some dramatic swings lately, stirring up plenty of debate among investors trying to make sense of its momentum. Over the past year, Kyndryl’s stock is up more than 30%, which is impressive, especially when compared to some of its peers. However, shorter-term moves have been more volatile, with a 1-day gain of...
NasdaqGS:MPWR
NasdaqGS:MPWRSemiconductor

Monolithic Power Systems (MPWR): Evaluating Valuation After Recent Share Price Dip

Monolithic Power Systems (MPWR) has seen a fresh wave of attention after its stock dipped slightly, closing 0.7% lower yesterday. While there is no headline-making news or AI announcement fueling the move, any quick turn in share price tends to stir up questions, especially with how dynamic the semiconductor sector has felt lately. For investors on the fence, even modest drops in a quality name like this can feel like either a warning sign or a window of opportunity. Taking a broader view,...